Impact of Extensive Drug Resistance on Treatment Outcomes in Non-HIV-Infected Patients with Multidrug-Resistant Tuberculosis

Abstract

The presence of extensive drug resistance, the presence of comorbidity, and hypoalbuminemia were independent poor prognostic factors in non-HIV-infected patients with MDR-TB.

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia

“…Table 2 presents the poor treatment outcomes of MDR-TB patients. The overall treatment success rate in this study for MDR-TB patients was 17.1%, which is lower than the reported success rates in European and South Korean studies (39%-54%) (17,18). MDR-TB occurrence in different parts of the world is an alarming phenomenon because of the poor therapeutic outcomes obtained when isolated strains were resistant to INH and RIF (9,19).…”

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

“…302 Other factors-such as HIV co-infection, previous history of tuberculosis treatment, resistance profile (MDR vs XDR vs other), extent of total and cavitary disease on chest radiograph, presence of comorbid conditions such as diabetes mellitus, and initial microbiological burden-might all have some role in predicting treatment response. [304][305][306] Therefore, the need to develop a composite tool that can predict long-term outcomes of failure and relapse is urgent. Such a tool, once validated, would have the potential to significantly shorten the approval of new interventions for MDR tuberculosis.…”

Risk Factors for Poor Treatment Outcomes in Patients With MDR-TB and XDR-TB in China: Retrospective Multicenter Investigation

“…Medical records from in-patient and out-patient treatments were reviewed for patients' demographics, TB treatment history, comorbidities, drug susceptibility test (DST) results, chest radiographs, treatment modalities and outcomes. According to previous studies [7][8][9][10][11] and our clinical experience, the comorbidities including diabetes, COPD, Chronic hepatitis, tumor, hepatic dysfunction and decreased albumin could be risk factors associated with poor treatment outcome among patients with MDR-and XDR-TB. Thus they were finally selected as variables.…”